Construction and identification of the replication-deficient recombinant vaccinia virus co-expressing HPV type 16 L1 and L2 proteins.
- Author:
Liqun HAN
1
;
Jiao REN
;
Yu LIANG
;
Houwen TIAN
;
Huijun ZHI
;
Weifeng LUO
;
Zhenhua LU
;
Lanlan WEI
;
Li RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Capsid; Capsid Proteins; genetics; Cell Line; Cloning, Molecular; Female; Gene Expression; Genetic Vectors; Humans; Oncogene Proteins, Viral; genetics; Papillomaviridae; genetics; physiology; Papillomavirus Infections; prevention & control; Transfection; Tumor Virus Infections; prevention & control; Uterine Cervical Neoplasms; virology; Vaccinia virus; genetics; physiology; Virus Replication
- From: Chinese Journal of Experimental and Clinical Virology 2002;16(3):256-260
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo generate an HPV16 prophylactic vaccine candidate for cervical cancer.
METHODSHPV16 major capsid protein L1 gene and minor capsid protein L2 gene were amplified using PCR. These genes were mutated by PCR site-directed mutagenesis for removal of sequence motifs (TTTTTNT) which would cause transcription termination when expressed from a vaccinia virus early promoter, then inserted into a vaccinia virus expression vector. A strain replication-deficient recombinant vaccinia virus containing the mutant sequences was obtained through a homologous recombination and identified.
RESULTSThe nucleotide sequence remained the correct amino acid sequence of the L1 and L2 proteins after mutated. Full-length L1 and L2 proteins were generated in cells infected with the recombinant virus. The virus strain propagated at very low titer or could not reproduce in some kinds of cell derived from different human tissues.
CONCLUSIONSThe authors have generated a strain replication-deficient recombinant vaccinia virus expressing HPV16 L1 plus L2 proteins as an HPV16 prophylactic vaccine candidate for cervical cancer.
